SI-BONE, Inc. (SIBN) Guidance & Earnings Results

On 2026-08-03 SI-BONE, Inc. raised guidance: "FY2026 revenue raised to $231-233M from $230-233M; gross margin ~79% (unchanged); operating expenses growth ~12% (from ~12.5%); adjusted EBITDA positive…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

SIBNSI-BONE, Inc.Follow SIBN — free

Medical Devices · Healthcare

—

Price chart with a free account

Market cap: 962.7M
P/E TTM: —
Dividend yield: 0.0%
52-week: —
Next earnings: 2 Nov, in 9 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
3 Aug 26	Raised	FY2026 revenue raised to $231-233M from $230-233M; gross margin ~79% (unchanged); operating expenses growth ~12% (from ~12.5%); adjusted EBITDA positive (unchanged) · full year
11 May 26	Raised	Revenue guidance raised to $230M-$233M (14-16% growth); gross margin raised to ~79% · full year
23 Feb 26	Raised	Issued 2026 guidance · full year
10 Nov 25	Raised	Revenue guidance raised to $198M-$200M from $195M-$198M · full year
4 Aug 25	Raised	2025 guidance raised; specific numbers not fully provided in excerpt but title indicates raise. Prior guidance not available in excerpt. · full year

SI-BONE, Inc. — questions

What guidance did SI-BONE, Inc. give?: On 2026-08-03: "FY2026 revenue raised to $231-233M from $230-233M; gross margin ~79% (unchanged); operating expenses growth ~12% (from ~12.5%); adjusted EBITDA positive (unchanged)"
When does SI-BONE, Inc. report earnings?: SI-BONE, Inc.'s next earnings report is expected on 2026-11-02.

Every figure on this page comes from SI-BONE, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.